|
Mutation Information
|
Mutation Site
|
Y181C |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
lamivudine (LAM) |
|
Country
|
Kenya |
Literature Information
|
PubMed PMID
|
31818716
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2020 |
|
Journal
|
The lancet. HIV |
|
Title
|
Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial. |
|
Author
|
Chung MH,McGrath CJ,Beck IA,Levine M,Milne RS,So I,Andersen N,Dross S,Coombs RW,Chohan B,Yatich N,Kiptinness C,Sakr SR,Kiarie JN,Frenkel LM |
|
Evidence
|
The OLA-guided therapy group had pre-ART peripheral blood mononuclear cells evaluated for drug resistance to non-nucleoside reverse transcriptase inhibitor (NNRTI) at codons Lys103Asn, Tyr181Cys, Gly190Ala, and to lamivudine at Met184Val, and when at least one drug-resistant codon was detected in a participant's pre-ART specimen, clinicians were directed to prescribe protease inhibitor-based second-line ART.
|
|
|
HIV Mutation Detail Information